Omnicell (OMCL) Stock
Medication management automation provider for hospitals and pharmacies. Here's the price, business snapshot, and what's worth knowing about Omnicell in October 2026.
Omnicell Inc (OMCL) designs and sells medication management and pharmacy automation solutions for hospitals, retail pharmacies and other healthcare providers. The business combines hardware (dispensing systems), software (workflow and analytics) and services (installation, maintenance, consumables), creating a mix of product sales and recurring revenue. With a market capitalisation of around $1.42 billion, Omnicell aims to help customers cut errors and improve efficiency, but growth depends on hospital capital cycles, technology adoption and competition. Investors should weigh the potential for steady service revenues and software uptake against execution and regulatory risks, competitive pressure and occasional lumpy sales. This summary is general information only and not personalised advice — prospective investors should review the latest regulatory filings, earnings reports and professional guidance before deciding whether OMCL fits their portfolio and risk tolerance.
Omnicell (OMCL) Stock Forecast
Analyst price target, next 12 months
$51.00
+38.1% vs today's $36.93
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Omnicell have a consensus 12-month target of $51.00, above the current price of $36.93.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Omnicell's stock with a target price of $51, indicating growth potential.
Financial Health
Omnicell is generating solid revenue and cash flow, with strong profitability indicators.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Automation and Efficiency
Automation of pharmacy workflows can reduce errors and operating costs, and long-term contracts may support recurring revenue, though adoption cycles can be lengthy.
Recurring Revenue Mix
Software licences, services and consumables provide steadier income than one-off equipment sales, yet competition and pricing pressure can affect margins.
Regulatory & Execution Risks
Regulation, product integration and successful execution on new offerings are important risks; outcomes can vary and investors should assess recent operational trends.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
